Trial · NCT06813079
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | 3 years | |
| Secondary | Disease control rate (DCR) | 3 years | |
| Secondary | Duration of response (DOR) | 3 years | |
| Secondary | Progression free survival (PFS) | 3 years | |
| Secondary | Overall survival (OS) | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort A assigned to cobimetinib | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort B assigned to cobimetinib | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort A assigned to ponatinib | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort B assigned to ponatinib | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort A assigned to brigatinib | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort B assigned to brigatinib | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort A assigned to colchicine | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort B assigned to colchicine | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort A assigned to selinexor | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort B assigned to selinexor | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort A assigned to ceritinib | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort B assigned to ceritinib | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort A assigned to abemaciclib | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort B assigned to abemaciclib | 3 years | |
| Secondary | Number of side effects experienced with participants in Cohort A assigned to neratinib | 3 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06813079/registered